In today’s highly charged political environment, it is challenging to find a topic where consensus outweighs our nation’s current discord. There is one issue, however, that an overwhelming number of American voters agree on: CBD – specifically, testing and regulating CBD to ensure safe, quality products.
Recent public opinion research conducted by Greenberg Quinlan Rosner found a huge majority – 83 percent of registered U.S. voters – believe that the Food and Drug Administration should be doing more to regulate CBD and protect consumers.
Why? Believe it or not, the vast majority of CBD products available today fail to meet safety standards and are not scientifically tested. This uncertainty puts consumers trying to make safe and healthy decisions at risk, in a rapidly growing marketplace where CBD is expected to reach $2 billion in the next few years. The polling results indicate that the Americans in every region of the country, across all political parties, and demographics are overwhelmingly concerned about the safety and efficacy of the CBD products.
Here’s a breakdown of our poll findings: In Southern states, 86 percent of respondents support testing and regulation, and 84 percent of respondents in Western states agreed. In the Northeast, 82 percent of consumers are looking to the FDA for guidance and 79 percent of those living in America’s heartland agreed. Across party lines, 87 percent of Democrats want the FDA to get involved, as do 81 percent of Republicans and Independents. Among voters, 85 percent of consumers under the age of 50 support testing and regulation, as do 81 percent of those over 50.
Voters have also been forthcoming about taking their concerns to the ballot box in November. More than half of respondents said they would vote for candidates who support requiring the FDA to regulate CBD products. These findings clearly indicate that voters want and need reliable information about CBD, safe packaging, accurate labeling, and reliability that concentration levels are not harmful. Our nation deserves the gold standard protection that the FDA has provided for decades. We can’t afford to wait.